ProQR and Eli Lilly work together on gene therapies

9 September 2021
eli_lilly_lab_large

Dutch biotech firm ProQR Therapeutics (Nasdaq: PRQR) has inked a global licensing and research collaboration with Eli Lilly (NYSE: LLY), worth over a billion dollars in the best case scenario.

The companies will work together on the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system.

ProQR brings to the table its proprietary Axiomer RNA editing platform, which will be used to progress new drug targets toward clinical development.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology